Insulet Corporation $PODD Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Insulet stake by 344.4% in the third quarter, acquiring 291,471 additional shares and ending with 376,104 shares worth approximately $49.1 million.
• Insulet reported stronger-than-expected quarterly results, with EPS of $1.66 versus the $1.47 consensus estimate and revenue of $801.7 million, up 23.5% year over year.
• Analyst sentiment is mixed: the stock has an overall “Hold” rating and a consensus price target of $186.68, while recent firms have significantly lowered targets despite several maintaining Buy or Outperform ratings.

Assenagon Asset Management S.A. boosted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 344.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 376,104 shares of the medical instruments supplier's stock after purchasing an additional 291,471 shares during the period. Assenagon Asset Management S.A. owned about 0.54% of Insulet worth $49,070,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Brindle & Bay Financial Advisors LLC purchased a new stake in shares of Insulet in the 3rd quarter valued at approximately $204,000. Retirement Planning Co of New England Inc. raised its holdings in shares of Insulet by 22.7% in the third quarter. Retirement Planning Co of New England Inc. now owns 3,285 shares of the medical instruments supplier's stock valued at $429,000 after buying an additional 607 shares during the last quarter. Signal Advisors Wealth LLC acquired a new stake in shares of Insulet during the third quarter worth about $210,000. Krilogy Financial LLC grew its position in Insulet by 46.9% in the 3rd quarter. Krilogy Financial LLC now owns 6,451 shares of the medical instruments supplier's stock valued at $902,000 after buying an additional 2,060 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC boosted its holdings in shares of Insulet by 4.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 3,194 shares of the medical instruments supplier's stock valued at $429,000 after acquiring an additional 134 shares in the last quarter.

Insulet Price Performance

Shares of NASDAQ PODD opened at $141.10 on Friday. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The business has a 50-day moving average of $140.56 and a 200-day moving average of $156.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company has a market capitalization of $9.79 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 1.11 and a beta of 1.11.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PODD. Raymond James Financial reiterated an "outperform" rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Truist Financial reiterated a "hold" rating and set a $153.00 target price (down from $210.00) on shares of Insulet in a research report on Wednesday, August 5th. Wells Fargo & Company downgraded shares of Insulet from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $255.00 to $144.00 in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Insulet in a report on Monday, September 21st. Finally, Stifel Nicolaus cut their target price on shares of Insulet from $225.00 to $180.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.